Sign In
Buy NUVL
$90.18
-1.17 (-1.28%)
At Close: Jun 03, 2026
Royalty Pharma Acquires Royalty Interest in Nuvalent's Neladalkib and Zidesamtinib for Up to $315 Million
07:15am, Tuesday, 16'th Dec 2025
NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a pre-existing royalty interest in Nuvalent's neladalkib and zidesamtinib from an und
Nuvalent Appoints Ron Squarer to Board of Directors
04:01pm, Wednesday, 10'th Dec 2025
CAMBRIDGE, Mass. , Dec. 10, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kin
Nuvalent, Inc. $NUVL Position Trimmed by Fisher Asset Management LLC
04:40am, Thursday, 04'th Dec 2025
Fisher Asset Management LLC decreased its holdings in Nuvalent, Inc. (NASDAQ: NUVL) by 5.4% during the undefined quarter, according to the company in its most recent disclosure with the SEC. The fund
Creative Planning Buys 9,079 Shares of Nuvalent, Inc. $NUVL
04:03am, Saturday, 29'th Nov 2025
Creative Planning increased its stake in shares of Nuvalent, Inc. (NASDAQ: NUVL) by 110.6% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commi
First Look: Campbell Soup fallout, Alphabet AI strength, Nvidia rebuttal
07:39am, Wednesday, 26'th Nov 2025
Stock News Campbell puts exec on leave: Campbell's Co. (CPB) sidelined a senior IT executive after a lawsuit and leaked audio alleged he disparaged customers an
Nuvalent to Participate in the Piper Sandler 37th Annual Healthcare Conference
06:30am, Wednesday, 26'th Nov 2025
CAMBRIDGE, Mass. , Nov. 26, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kin
Market Today: Stocks Rise on Fed Cut Bets; Alphabet, Apple Hit Records
06:00pm, Tuesday, 25'th Nov 2025
Guru Stock PicksJefferies Group has made the following transactions:Reduce in CLDX by 12.28%Sold out in UNFIAdd in SMH by 25.28%New position in XNCRT Rowe Price
CAMBRIDGE, Mass. , Nov. 24, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase
NDA based on data from global ARROS-1 Phase 1/2 clinical trial FDA assigns PDUFA target action date of September 18, 2026 CAMBRIDGE, Mass. , Nov. 19, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL)
Biotech Stock Gets Booted in Latest Fund Update
11:56am, Wednesday, 19'th Nov 2025
Sold 1,447,267 shares, a net position change of $110.43 million Post-trade stake: 0 shares, $0 value The position was previously 13.8% of the fund's AUM as of the prior quarter, marking a significant
Nuvalent Announces Pricing of Public Offering of Common Stock
11:50pm, Tuesday, 18'th Nov 2025
CAMBRIDGE, Mass. , Nov. 18, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase
Nuvalent Announces Public Offering of Common Stock
04:01pm, Monday, 17'th Nov 2025
CAMBRIDGE, Mass. , Nov. 17, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinas
Nuvalent, Inc. ( NUVL ) Discusses Topline Pivotal Data From ALKOVE-1 Trial of Neladalkib in ALK-Positive Non-Small Cell Lung Cancer November 17, 2025 8:00 AM EST Company Participants Chelcie Lister Ja
Nuvalent Reports 31% Response Rate In Patients With Advanced Form Of Lung Cancer
01:03pm, Monday, 17'th Nov 2025
Nuvalent, Inc. (NASDAQ: NUVL) on Monday reported topline results from its ALKOVE-1 Phase 1/2 trial.
In 253 ALK TKI pre-treated patients, ORR by BICR was 31% (95% CI: 26, 37), with initial estimated durability of response of 64% and 53% at the 12-month and 18-month landmarks, respectively In the subs
